Listing 1 - 10 of 12 | << page >> |
Sort by
|
Choose an application
Functional evidence obtained from somatic cell fusion studies indicated that a group of genes from normal cells might replace or correct a defective function of cancer cells. Tumorigenesis that could be initiated by two mutations was established by the analysis of hereditary retinoblastoma, which led to the eventual cloning of RB1 gene. The two-hit hypothesis helped isolate many tumor suppressor genes (TSG) since then. More recently, the roles of haploinsufficiency, epigenetic control, and gene dosage effects in some TSGs, such as P53, P16 and PTEN, have been studied extensively. It is now widely recognized that deregulation of growth control is one of the major hallmarks of cancer biological capabilities, and TSGs play critical roles in many cellular activities through signaling transduction networks. This book is an excellent review of current understanding of TSGs, and indicates that the accumulated TSG knowledge has opened a new frontier for cancer therapies.
Antioncogenes. --- Anti-oncogenes --- Cancer suppressor genes --- Emerogenes --- Tumor suppressing genes --- Tumor suppressor genes --- Cancer genes --- Tumor suppressor proteins --- Oncology
Choose an application
Tumor suppressor genes (TSGs) and their signaling networks are fast growing areas in current biomedical science. These groups of genes, which are not limited to tumor suppression, play critical roles in many cellular activities. This book, "Future Aspects of Tumor Suppressor Genes", contains some fascinating fields, from basic to translational researches, in recent TSG studies. For example, several TSG signaling pathways are addressed in this book, and both mouse and Drosophila models used for the exploration of these genes are described based on the experimental evidence. A detailed review for current knowledge of microRNA studies in the regulation of tumor growth is introduced. Additionally, how natural compounds interfere with the progression of cancer development via TSG pathways is systemically summarized. Recent progresses in cell reprogramming and stemness transition processes regulated by TSG pathways are also included in this book.
Antioncogenes. --- Anti-oncogenes --- Cancer suppressor genes --- Emerogenes --- Tumor suppressing genes --- Tumor suppressor genes --- Cancer genes --- Tumor suppressor proteins --- Molecular biology
Choose an application
The Second Edition of The Oncogene and Tumour Suppressor Gene FactsBook has been completely revised, updated, and expanded by 60%. The book contains more than 80 entries on oncogenes including JUN, MYC, and RAS, as well as DNA tumour viruses, tumour suppressor genes, including p53, retinoblastoma, BRCA1, BRCA2, VHL, F2FL, and essential material on angiogenesis and metastasis, apoptosis, cell cycle control, and gene therapy.Key Features* Includes much new data on this fast-moving field, including newly discovered oncogenes* Summarizes the clinical associatio
Oncogenes. --- Antioncogenes. --- Anti-oncogenes --- Cancer suppressor genes --- Emerogenes --- Tumor suppressing genes --- Tumor suppressor genes --- Onc genes --- Cancer genes --- Tumor suppressor proteins --- Proto-oncogenes --- Antioncogenes --- Oncogenes
Choose an application
Antioncogenes. --- Tumor suppressor proteins. --- Antioncoproteins --- Growth suppressor proteins --- Metastasis suppressor proteins --- Proteins --- Antioncogenes --- Anti-oncogenes --- Cancer suppressor genes --- Emerogenes --- Tumor suppressing genes --- Tumor suppressor genes --- Cancer genes --- Tumor suppressor proteins
Choose an application
The underlying idea that cancer is a genetic disease at the cellular level was postulated over 75 years ago when Boveri hypothesised that the malignant cell was one that had obtained an abnormal chromatin content. However, it has been only the last decade where enormous strides have been made toward understanding neoplastic development. Explosive growth in the discipline of cancer genetics is so rapid that any attempt to review this subject becomes rapidly outdated and continuous revisions are warranted. Conclusive evidence has been reached associating specific chromosomal abnormalities to var
Antioncogenes. --- Cancer --- Oncogenes. --- Tumors --- Onc genes --- Cancer genes --- Proto-oncogenes --- Cancer genetics --- Anti-oncogenes --- Cancer suppressor genes --- Emerogenes --- Tumor suppressing genes --- Tumor suppressor genes --- Tumor suppressor proteins --- Genetic aspects.
Choose an application
Tumor Suppressing Viruses, Genes, and Drugs profiles the new generation of cancer treatments now in development. The book examines the innovative new approaches of viral, gene, and signal therapies that promise to replace or enhance conventional methods such as surgery, radiation, and chemotherapy. The timely information presented by this book should be of interest to anyone concerned with advancing cancer treatment beyond current medical practices.
Antioncogenes. --- Cancer --- Viruses --- Genetic vectors --- Microorganisms --- Mobile genetic elements --- Extrachromosomal DNA --- Anti-oncogenes --- Cancer suppressor genes --- Emerogenes --- Tumor suppressing genes --- Tumor suppressor genes --- Cancer genes --- Tumor suppressor proteins --- Gene therapy. --- Therapeutic use. --- Treatment --- Technological innovations. --- Molecular aspects. --- Genetic aspects --- Antioncogènes --- Thérapie génique --- Aspect moléculaire
Choose an application
This Urological Cancer 2020 collection contains a set of multidisciplinary contributions to the extraordinary heterogeneity of tumor mechanisms, diagnostic approaches, and therapies of the renal, urinary tract, and prostate cancers, with the intention of offering to interested readers a representative snapshot of the status of urological research.
renal cell carcinoma --- iron --- macrophages --- chelation therapy --- urothelial carcinoma --- transcriptome --- microtubule --- MAP1B --- prognosis --- KLF5 --- androgen receptor --- cell proliferation --- tumorigenesis --- prostate cancer --- precision medicine --- whole genome sequencing --- optical mapping --- therapy --- prostate carcinoma --- prostate mpMRI --- machine learning --- artificial intelligence --- deep learning --- neural network --- angiogenesis --- angiogenic growth factors --- antiangiogenic therapy --- renal tumors --- prevention --- α1-adrenoceptor antagonists --- anoikis --- vascularity --- research model --- oncogenes --- tumor suppressor genes --- MR-guided --- radiotherapy --- MRgRT --- stereotactic ablative radiotherapy --- stereotactic ablative radiation therapy (SABR) --- renal cell cancer --- RCC --- online adaptive --- [68Ga]Ga-PSMA PET/CT --- dual-time point imaging --- delayed imaging --- biphasic imaging --- lesion positivity rate --- CXCL9 --- PD1 --- PD-L1 --- stage T1 NMIBC --- prostatic neoplasms/mortality --- prostatic neoplasms/epidemiology --- SEER Program --- bladder cancer --- transurethral resection --- en-bloc resection --- CPT1A --- fatty acids --- serine --- androgen response --- ROS --- oxidative stress --- DONSON --- Downstream Neighbor of SON --- biomarker --- metastatic spread --- diagnosis --- differential diagnosis --- histopathology --- immunohistochemistry --- stroma signature --- patient-derived xenografts --- n/a --- Research. --- Biology.
Choose an application
This book includes 17 papers published in the Special Issue/Article Collection “New Insights in the Genetics and Genomics of adrenocortical tumors and pheochromocytomas” including an editorial, 10 research papers and six review articles. Adrenal tumors represent a hot topic in contemporary endocrine oncology. Significant advancements in the genetics of genomics of these tumors have been made in recent years, and these articles give a useful and comprehensive overview of these issues. Questions regarding molecular pathogenesis, diagnosis (biomarkers) and even treatment are discussed in the papers written by international leaders of the field. Manuscripts are focused on three main topics: i. primary aldosteronism (the most common cause of secondary endocrine hypertension), ii. adrenocortical cancer and iii. pheochromocytoma/paraganglioma, which are the tumors with the highest heritability in humans. The book is edited by Prof. Peter Igaz (Department of Endocrinology, Faculty of Medicine, Semmelweis University).
pheochromocytoma --- paraganglioma --- genetics --- non-coding RNA --- malignancy --- biomarker --- treatment --- adaptive metabolism --- adrenal gland --- conn adenoma --- fatty acid metabolism --- ferroptosis --- hyperaldosteronism --- metabolic reprogramming --- β-oxidation --- PPARα --- tumor microenvironment --- Next Generation Sequencing --- hereditary cancer --- endocrine tumor syndrome --- KCNJ5 somatic mutation --- pulse wave velocity --- aldosterone-producing adenoma --- adrenalectomy --- propensity score matching --- arterial stiffness --- pheochromocytomas --- paragangliomas --- mutations --- susceptibility genes --- driver mutations --- hereditary --- germline --- somatic --- environment --- variants --- tumor suppressor genes --- metastatic --- RNAseq --- next generation sequencing --- adrenocortical carcinoma --- in silico analysis --- machine learning --- bioinformatic clustering --- biomarker prediction --- aldosterone producing adenoma --- ATP2B3 --- K416-F418delinsN mutation --- primary aldosteronism --- PPGL --- telomeres --- TERT --- ATRX --- NOP10 --- prognostic biomarker --- ALT --- phaeochromocytoma --- cancer --- mitochondrial complex II --- zebrafish --- therapy --- drug discovery --- redox balance pathway --- Vitamin C --- mitotane --- H295 strains --- microRNA --- aldosterone --- circulating --- adrenocortical --- transcriptomics --- epigenetics --- metabolomics --- epidemiology --- genetic analysis --- mortality --- surveillance --- TP53 R337H --- genetic testing --- adrenocortical tumor --- neonatal screening --- screening --- adenoma --- adrenal --- tissue --- artificial intelligence --- neural network --- n/a
Choose an application
Natural compounds, from terrestrial and marine sources, are the result of an evolutionary process which originated in compounds with great structural diversity, multiple biological activities and miscellaneous applications. A large and very active research field is dedicated to identifying biosynthesized compounds; to improve/develop new methodologies to produce/reuse natural compounds; to assess their potential; and to understand their mechanism of action. This Special Issue brings together excellent original and review works, focused on the most recent advances related to the secondary metabolites’ composition of natural sources, and the proposal of new applications for their constituents, such as therapeutic agents, and pesticides or food ingredients.
heterologous expression --- Streptomyces --- secondary metabolite --- Garcinia xanthochymus --- growth inhibitory compounds --- allelopathy --- vanillic acid --- methyl phloretate --- allelopathic activity --- growth inhibitor --- phenolic compounds --- bioherbicide --- sustainable agriculture --- pulsed electric fields --- green extraction --- microalgae --- antioxidants --- pigments --- thymoquinone --- UHRF1 --- ubiquitination --- HAUSP --- tumor suppressor genes --- aaptoline B --- pyrroloquinoline --- Ag(I)-catalyzed cycloisomerization --- dopaminergic neuroprotection --- Parkinson’s disease --- bioactive compounds --- cardiovascular --- nanodelivery --- bioavailability --- Ailanthus altissima --- biological properties --- analytical techniques --- potential applications --- propolis contamination --- propolis cytotoxicity --- antimicrobial activity --- antiprotozoal activity --- artepelin C --- formononetin --- pinocembrin --- quercetin --- kaempferol --- propolis extract --- Asparagopsis armata --- Rhodophyta --- GC-MS --- UHPLC-MS --- dibrominated compounds --- 1,4-dibromobuten-1-ol --- palmitic acid --- brominated phenolics --- red seaweed --- invasive seaweed --- invasive species --- flowers --- antioxidant --- microbial activity --- bioactivity --- enzyme inhibitory potential --- acetylcholinesterase --- lipase --- α-glucosidase --- n/a --- Parkinson's disease
Choose an application
This book includes 17 papers published in the Special Issue/Article Collection “New Insights in the Genetics and Genomics of adrenocortical tumors and pheochromocytomas” including an editorial, 10 research papers and six review articles. Adrenal tumors represent a hot topic in contemporary endocrine oncology. Significant advancements in the genetics of genomics of these tumors have been made in recent years, and these articles give a useful and comprehensive overview of these issues. Questions regarding molecular pathogenesis, diagnosis (biomarkers) and even treatment are discussed in the papers written by international leaders of the field. Manuscripts are focused on three main topics: i. primary aldosteronism (the most common cause of secondary endocrine hypertension), ii. adrenocortical cancer and iii. pheochromocytoma/paraganglioma, which are the tumors with the highest heritability in humans. The book is edited by Prof. Peter Igaz (Department of Endocrinology, Faculty of Medicine, Semmelweis University).
Medicine --- pheochromocytoma --- paraganglioma --- genetics --- non-coding RNA --- malignancy --- biomarker --- treatment --- adaptive metabolism --- adrenal gland --- conn adenoma --- fatty acid metabolism --- ferroptosis --- hyperaldosteronism --- metabolic reprogramming --- β-oxidation --- PPARα --- tumor microenvironment --- Next Generation Sequencing --- hereditary cancer --- endocrine tumor syndrome --- KCNJ5 somatic mutation --- pulse wave velocity --- aldosterone-producing adenoma --- adrenalectomy --- propensity score matching --- arterial stiffness --- pheochromocytomas --- paragangliomas --- mutations --- susceptibility genes --- driver mutations --- hereditary --- germline --- somatic --- environment --- variants --- tumor suppressor genes --- metastatic --- RNAseq --- next generation sequencing --- adrenocortical carcinoma --- in silico analysis --- machine learning --- bioinformatic clustering --- biomarker prediction --- aldosterone producing adenoma --- ATP2B3 --- K416-F418delinsN mutation --- primary aldosteronism --- PPGL --- telomeres --- TERT --- ATRX --- NOP10 --- prognostic biomarker --- ALT --- phaeochromocytoma --- cancer --- mitochondrial complex II --- zebrafish --- therapy --- drug discovery --- redox balance pathway --- Vitamin C --- mitotane --- H295 strains --- microRNA --- aldosterone --- circulating --- adrenocortical --- transcriptomics --- epigenetics --- metabolomics --- epidemiology --- genetic analysis --- mortality --- surveillance --- TP53 R337H --- genetic testing --- adrenocortical tumor --- neonatal screening --- screening --- adenoma --- adrenal --- tissue --- artificial intelligence --- neural network
Listing 1 - 10 of 12 | << page >> |
Sort by
|